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Clinical and Epidemiological Implications of 24-Hour Ambulatory
Blood Pressure Monitoring for the Diagnosis of Hypertension in
Kenyan Adults: A Population-Based Study
Anthony O. Etyang, MBChB, MMed, MSc; Ben Warne, MB, BChir, MRCP, DTM&H; Sailoki Kapesa, Dip Clin Med & Surg;
Kenneth Munge, MBChB, MPH; Evasius Bauni, PhD; J. Kennedy Cruickshank, MBChB, MD, FRCP; Liam Smeeth, PhD, FRCGP, FMedSci;
J. Anthony G. Scott, FRCP
Background-—The clinical and epidemiological implications of using ambulatory blood pressure monitoring (ABPM) for the
diagnosis of hypertension have not been studied at a population level in sub-Saharan Africa. We examined the impact of ABPM use
among Kenyan adults.
Methods and Results-—We performed a nested case–control study of diagnostic accuracy. We selected an age-stratiﬁed random
sample of 1248 adults from the list of residents of the Kiliﬁ Health and Demographic Surveillance System in Kenya. All participants
underwent a screening blood pressure (BP) measurement. All those with screening BP ≥140/90 mm Hg and a random subset of
those with screening BP <140/90 mm Hg were invited to undergo ABPM. Based on the 2 tests, participants were categorized as
sustained hypertensive, masked hypertensive, “white coat” hypertensive, or normotensive. Analyses were weighted by the
probability of undergoing ABPM. Screening BP ≥140/90 mm Hg was present in 359 of 986 participants, translating to a crude
population prevalence of 23.1% (95% CI 16.5–31.5%). Age standardized prevalence of screening BP ≥140/90 mm Hg was 26.5%
(95% CI 19.3–35.6%). On ABPM, 186 of 415 participants were conﬁrmed to be hypertensive, with crude prevalence of 15.6% (95%
CI 9.4–23.1%) and age-standardized prevalence of 17.1% (95% CI 11.0–24.4%). Age-standardized prevalence of masked and white
coat hypertension were 7.6% (95% CI 2.8–13.7%) and 3.8% (95% CI 1.7–6.1%), respectively. The sensitivity and speciﬁcity of
screening BP measurements were 80% (95% CI 73–86%) and 84% (95% CI 79–88%), respectively. BP indices and validity measures
showed strong age-related trends.
Conclusions-—Screening BP measurement signiﬁcantly overestimated hypertension prevalence while failing to identify 50% of
true hypertension diagnosed by ABPM. Our ﬁndings suggest signiﬁcant clinical and epidemiological beneﬁts of ABPM use for
diagnosing hypertension in Kenyan adults. ( J Am Heart Assoc. 2016;5:e004797, doi: 10.1161/JAHA.116.004797)
Key Words: ambulatory blood pressure monitoring • diagnostic accuracy • hypertension •masked hypertension • sub-Saharan
Africa • white coat hypertension
A cross sub-Saharan Africa (sSA), numerous studies havebeen conducted to estimate the prevalence of hyper-
tension in various settings.1,2 These data are necessary for
planning public health activities, especially given the pro-
jected increase in the burden of noncommunicable disease in
the region.3 Nevertheless, a substantial amount of commu-
nicable disease remains, increasing the need for accurate
data to guide resource allocation among competing health
priorities.4
The measurement of blood pressure (BP) is subject to
multiple sources of variation5 that will have an impact on both
the epidemiology and the clinical management of hyperten-
sion. Measurement error arising from technical problems has
been minimized by using validated criteria for BP monitors.6 It
is possible to minimize observer error in reading BP values by
using automated devices and following a deﬁned measure-
ment procedure. Despite such improvements, these protocols
provide only a momentary assessment of BP, which can be
inﬂuenced by a variety of environmental and psychological
factors.7 Ambulatory BP monitoring (ABPM) reduces this
limitation and is increasingly used for both clinical and
epidemiological purposes.7,8 In high-income settings, ABPM is
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a signiﬁcantly better predictor of future cardiovascular risk
than ofﬁce or home measurement.7 It is also the only way to
detect abnormal nocturnal dipping patterns that are an
independent risk factor for future cardiovascular events9 and
that appear to be more common in populations of African
descent.10,11 In addition, ABPM enables the measurement of
the ambulatory arterial stiffness index, an independent
predictor of cardiovascular outcomes, especially stroke.12
The use of ABPM facilitates better prescription patterns
among established hypertensive patients and helps identify
patients with masked hypertension and those with abnormal
dipping patterns who would otherwise be missed when using
casual (standard) BP measurement methods. The increased
diagnostic performance of ABPM makes it cost effective in
both primary and specialist care in developed-world set-
tings.13,14 The high initial cost of ABPM devices has precluded
their widespread use in low-income settings in sSA, and there
is little information to assess the potential clinical and public
health beneﬁts of ABPM in such settings.
We conducted Shinikizo la Damu (ShinDa), a population-
based study, in rural coastal Kenya to determine 24-hour BP
proﬁles in adults and to compare these with parameters
derived from screening BP measurements.
Methods
This study was conducted from April 2013 to May 2014 in the
Kiliﬁ Health and Demographic Surveillance System (KHDSS)
located along the coast of Kenya. The 900 km2 covered by
the KHDSS and a population of 300 000 people makes it one
of the largest demographic surveillance areas in Africa both in
terms of area and population.15 Within the KHDSS, the total
fertility rate (4.73), the crude birth rate (34.7 per 1000
annually), the population growth rate (2.79% per year), and the
proportion of the population aged <15 years (49%) are similar
to rates across Kenya. However, the mortality ratio for
children aged <5 years (41 per 1000 births) and HIV
prevalence (4.9% among antenatal clinic attendees) are lower
than the national averages (74 per 1000 births and 8.0%,
respectively).16 We have previously documented a double
burden of infectious and noncommunicable diseases in the
area, similar to other parts of the developing world.17
We selected an age-stratiﬁed random sample of 1248
adults from the list of KHDSS residents. The sample size was
designed to generate a population-level estimate of the true
prevalence of hypertension with conﬁdence intervals of
approximately 5%. We previously documented a signiﬁcant
distance-related bias in presentation to the hospital in the
study area.17 To minimize this bias, study procedures were
carried out at the participants’ homesteads. Trained staff
visited all participants who were selected to participate in the
study at their homes. A total of 3 attempts were made at
ﬁnding a selected participant before concluding that the
participant could not be found. No replacement was done for
participants who could not be found. Women who reported
that they were pregnant were excluded from the study.
We used a nested case–control diagnostic accuracy study
design in which all participants with elevated screening BP
and a random subset of those with normal screening BP were
invited to undergo ABPM.18 We weighted analyses to account
for differential probability of undergoing ABPM based on the
result of screening BP measurement.18 We aimed to have 24-
hour ABPM performed on equal numbers of participants with
and without elevated screening measurements (≥140/
90 mm Hg), assuming that the prevalence of elevated
screening BP would be 30%.
All participants were ﬁrst asked whether they had a previous
diagnosis of hypertension and whether they were on antihy-
pertensive medication. We then took a screening BP measure-
ment using a validated Omron M10-IT BP monitor. An
appropriately sized cuff was placed on the nondominant arm
after the participant was seated for at least 5 minutes. Three BP
measurements were taken over a 5-minute period, and the
mean of the last 2 measurements was recorded as the
screening BP value. All participants whose screening BP was
≥140 and/or 90 mm Hg were invited to undergo 24-hour
ABPM. A random sample of 292 (30%) of patients with
screening BP <140/90 mm Hg were invited for ABPM, and
analyses were weighted (see the “Statistical Methods” section)
to account for this. We used validated Omron M24/7 ambu-
latory BP monitors for the 24-hour ABPMmeasurements.19 The
monitors were programmed to take BPmeasurements every 20
to 30 minutes from6 AM to 10 PM and every 40 minutes from10
PM to 6 AM. ABPMwas performedwithin 1 week of the screening
BP measurements in all cases. The same ﬁeld staff conducted
the screening and assessed ABPM measurements and was not
blinded to any of the results.
A subset of 200 participants was selected at random from
the original sample of 1248 and asked to participate in
additional investigations. We ﬁrst measured their weight and
height using a validated Seca 874 ﬂat scale and a portable
stadiometer (Seca 213), respectively. We then requested
participants to provide a spot urine sample and a 24-hour
urine sample for determination of sodium, potassium, albu-
min, and creatinine levels.
Statistical Methods
ABPM data were excluded from the analyses if they failed the
following criteria, as speciﬁed by the European Society of
Hypertension: minimum 20 daytime and minimum 7 nighttime
readings, for which day was deﬁned as 9 AM to 9 PM and night
was deﬁned as 1 AM to 6 AM.7 The same time periods were
used to determine average daytime and nighttime BPs and to
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evaluate dipping status. Time weighting was applied in
calculating average BP values for all time periods.20
We deﬁned screen-positive participants as those whose
last 2 screening BP measurements had a mean ≥140/
90 mm Hg, and conﬁrmed hypertensive participants were
deﬁned as those who met any of the following 3 criteria: 24-
hour BP average ≥130/80 mm Hg, isolated daytime hyper-
tension (daytime BP average ≥135/85 mm Hg and nighttime
BP average <120/70 mm Hg), and isolated nocturnal hyper-
tension (nighttime BP average ≥120/70 mm Hg and daytime
BP average <135/85 mm Hg).7
Validity measures were computed using data from partic-
ipants who were not taking antihypertensive medications. We
categorized these participants using the combination of
screening BP measurements and ABPM into 4 groups:
sustained hypertensive (screen-positive and conﬁrmed
Figure 1. Study recruitment proﬁle. ABPM indicates ambulatory blood pressure monitoring; BP, blood
pressure; KHDSS, Kiliﬁ Health and Demographic Surveillance System.
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hypertensive on ABPM), “white coat” hypertensive (screen-
positive but not conﬁrmed hypertensive on ABPM), masked
hypertensive (screen-negative but conﬁrmed hypertensive on
ABPM), or normotensive (screen-negative and not conﬁrmed
hypertensive on ABPM).21 The 4 categories were used to
compute age-stratiﬁed measures of validity of the screening
BP measurements with ABPM as the reference standard.22,23
All summary measures were weighted according to the
probability of investigation with ABPM in the design.24
Conﬁdence intervals for these measures were obtained using
the recommended bootstrap procedure with 1000 replica-
tions.24
Among participants who reported that they were taking
antihypertensive medications, those who met the criteria for
white coat hypertension were labeled as having pseudoresis-
tant hypertension,7 whereas those who met the criteria for
masked hypertension were labeled as masked uncontrolled
hypertensive.7
Dipping status was deﬁned using ABPM data only, using
previously described methods.25
We computed 2 additional indices using the ABPM data—
24-hour pulse pressure (the mean of the differences between
systolic and diastolic BP values) and the ambulatory arterial
stiffness index—using previously published methods.26
We calculated the local prevalence of each index by
weighting the age-speciﬁc proportions by the age structure of
the Kiliﬁ population. Age standardization for all summary
population parameters was performed using weights derived
from the World Health Organization standard population.27
Summary statistics included means, medians, proportions,
and rates, as appropriate.
All analyses were conducted using Stata version 12
software (StataCorp).
The Kenya Medical Research Institute’s ethics review
committee approved the study, and all participants provided
written informed consent.
Table 1. Characteristics of Study Participants
All (N=986)
Selected to Undergo
ABPM (n=651)
ABPM Performed
(n=477)
Women, n (%) 588 (60) 400 (61) 302 (63)
Age in years, mean (SD) 50 (19) 53 (18) 54 (18)*
Screening BP in mm Hg, mean (SD)
Systolic 134 (26) 142 (28) 139 (28)*
Diastolic 81 (13) 84 (15) 82 (15)
BMI, kg/m2 (median, IQR)† 21 (19–24) 21 (19–24) 21 (19–23)
Na excretion, mmol/24 h (median, IQR)† 63 (47–92) 62 (47–90) 61 (47–80)
K excretion, mmol/24 h (median, IQR)† 25 (18–38) 25 (19–38) 25 (19–38)
Spot urine albumin:creatinine ratio, mg/mg (median, IQR)† 0.02 (0.01–0.04) 0.02 (0.01–0.04) 0.02 (0.01–0.04)
On medication for hypertension, n (%) 22 (2) 16 (2) 7 (1)
ABPM indicates ambulatory blood pressure monitoring; BMI, body mass index; BP, blood pressure; IQR, interquartile range.
*P<0.001 comparison between all screened participants (N=986) and those who underwent ABPM (n=477).
†BMI, Na, K, urine albumin:creatinine ratio based on 164 participants.
Figure 2. Comparison of screening and ABPM blood pressure
distributions. A, Systolic. B, Diastolic. ABPM indicates ambulatory
blood pressure monitoring.
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Results
Of the 1248 patients selected to participate in the study,
1150 (92%) were found at home and invited to participate in
the study. Of these, 986 (86%) gave consent and underwent
screening BP measurement (Figure 1). Of these, 359 (36%)
participants were screen-positive for hypertension (screening
BP ≥140/90 mm Hg). All 359 screen-positive and 292
screen-negative participants were invited to undergo ABPM.
Of all those invited to undergo ABPM, 477 (73%) actually
underwent it. Of the 200 participants selected to have urine
electrolyte and anthropometric measurements, 164 (82%) did
so.
Table 1 compares the characteristics of all 986 partici-
pants who had screening BP measurements, the subset of
651 selected to undergo ABPM, and the 477 who actually
underwent ABPM. The group that had ABPM performed had
higher screening systolic BP (+5 mm Hg, 95% CI 4.2–5.9) and
were older (+3.9 years, 95% CI 3.4–4.3) compared with the
entire group of participants selected for the study. There were
no signiﬁcant differences between those selected to undergo
ABPM (n=651) and those who actually underwent the
procedure (n=477).
Of the 477 participants who underwent ABPM, 415 (87%)
had acceptable readings; unacceptable readings (<20 daytime
and/or <7 nighttime) were signiﬁcantly more common among
screen-negative than screen-positive participants (17% versus
11%, P=0.036). Data from participants with unacceptable
ABPM readings were dropped from further analyses.
Six of the 415 participants with acceptable ABPM record-
ings were on antihypertensive medication.
Relationship Between Screening BP
Measurements and ABPM-Derived Measures
Among the 415 participants who had both screening and 24-
hour ABPM measurements, mean screening systolic and
diastolic BPs were 140 mm Hg (95% CI 138–143) and
84 mm Hg (95% CI 83–85), respectively. Corresponding
mean 24-hour ABPM systolic and diastolic BPs were
123 mm Hg (95% CI 121–125) and 72 mm Hg (95% CI 71–
73). The average difference between mean systolic screening
and 24-hour ABPM values was 16.8 mm Hg (95% CI 15–
18.6). Mean screening diastolic BPs were 12.2 mm Hg (95%
CI 11.2–13.2) higher than corresponding 24-hour ABPM
values (Figure 2).
Age-standardized mean screening systolic and diastolic
BPs for the population in Kiliﬁ were 128 mm Hg (95% CI 102–
162) and 79 mm Hg (95% CI 62–101), respectively. The 24-
hour mean systolic and diastolic BPs for the population were
117 mm Hg (95% CI 114–120) and 70 mm Hg (95% CI 68–
72), respectively. Ta
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ABPM-derived mean BPs were lower than those obtained
using screening measurement methods for all age groups
(Table 2). The relationship between 24-hour ABPM-derived
parameters (except for ambulatory arterial stiffness index and
diastolic BPs) and age approximated a J shape. Mean
ambulatory arterial stiffness index and pulse pressure
increased linearly with age (0.03 [95% CI 0.02–0.05] and
3.3 [95% CI 1.5–5], respectively) per 10-year increase in age.
The difference between ABPM-derived and screening BP
values increased with age.
Prevalence of Hypertension Using Casual BP
Measurement and ABPM
All reported KHDSS population parameters are age standard-
ized unless otherwise speciﬁed. The crude prevalence of
hypertension in the KHDSS using screening measurements
only was 23.1% (95% CI 16.5–31.5%). The crude prevalence of
hypertension in the KHDSS using ABPM was 15.6% (95% CI
9.4–23.1%). Using only screening BP values, the reported age-
standardized prevalence of hypertension would have been
26.5% (95% CI 19.3–35.6%). The age-standardized prevalence
of true hypertension (as determined by ABPM) in the KHDSS
was 17.1% (95% CI 11.0–24.4) (Table 2). There was a marked
increase in prevalence of screen-positive participants and true
hypertension with increasing age (Table 3).
The prevalence of masked hypertension overall was 7.6%
(95% CI 2.8–13.7%), and this was inversely associated with
increasing age. White coat hypertension was present in 3.8%
(95% CI 1.7–6.1%) of the population, and its prevalence
increased with age. The nondipping BP pattern was present in
8.5% (95% CI 3.1–15.3%) of the population, its prevalence
being highest in the 70- to 79-year age band. Figure 3
displays the standardized population prevalence of screen-
positive, true hypertensive, white coat hypertensive, masked
hypertensive, and nondipping participants.
Two of the 6 participants on antihypertensive medication
who underwent ABPM had pseudoresistant hypertension. No
cases of masked uncontrolled hypertension were detected.
Validity of Screening BP Measurements
The overall sensitivity and speciﬁcity of screening BP
measurements for diagnosing hypertension in the population
were 80% (95% CI 73–86%) and 84% (95% CI 79–88%),
respectively. Sensitivity improved with increasing age,
whereas speciﬁcity decreased (Table 4). Overall positive and
negative predictive values were 80% (95% CI 74–85%) and
Table 3. Age-Speciﬁc Prevalence of Hypertension Using Screening Measurement Method and ABPM
Age, y Screen-Positive HTN* Masked HTN† White Coat HTN‡ Nondipping Status§
18–29 11.0 (6.5–17.3) 10.9 (4.3–19.5) 10.9 (4.3–19.5) 2.9 (1.5–4.4) 6.5 (0.0–15.2)
30–39 13.1 (8.1–20.1) 12.5 (5.7–21.2) 11.5 (4.9–19.7) 1.0 (0.2–2.0) 9.8 (3.3–18.0)
40–49 26.8 (19.3–36.2) 11.0 (6.5–16.1) 4.5 (1.1–9.0) 3.7 (1.6–6.2) 5.3 (2.0–9.5)
50–59 43.8 (34.4–55.0) 20.2 (15.6–25.5) 2.8 (0.7–5.6) 7.0 (3.8–10.3) 6.8 (3.6–10.7)
60–69 55.4 (44.7–67.8) 33.4 (27.7–39.2) 3.1 (1.0–5.7) 3.9 (1.3–7.1) 12.1 (7.7–16.5)
70–79 65.0 (51.4–81.1) 47.1 (39.7–52.6) 2.7 (0.5–4.8) 10.0 (5.0–16.0) 24.2 (17.4–31.0)
≥80 68.8 (47.3–96.6) 46.9 (35.2–58.3) 3.9 (0.0–7.8) 8.6 (0.0–17.2) 12.2 (4.0–22.4)
Allk 26.5 (19.3–35.6) 17.1 (11.0–24.4) 7.6 (2.8–13.7) 3.8 (1.7–6.1) 8.5 (3.1–15.3)
ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; HTN, hypertension.
*Hypertension deﬁned according to European Society of Hypertension 2013 guidelines7: 24-hour BP >130/80 mm Hg or daytime BP >135/85 mm Hg or nocturnal BP >120/70 mm Hg.
Nighttime was deﬁned as 1 AM to 6 AM. Daytime was deﬁned as 9 AM to 9 PM.7
†Masked HTN: casual BP <140/90 mm Hg but meets criteria for HTN on ABPM.7 Participants with masked HTN were included in the group with true HTN.
‡White coat HTN: Casual BP >140/90 mm Hg but does not meet criteria for HTN on ABPM.7
§Nondipping status: ratio of average nighttime BP to average daytime BP ≥1.0.
kSummary prevalences are age standardized to the World Health Organization population.
Figure 3. Population prevalence of different blood pressure
indices. Data are derived from Table 3. HTN indicates hyperten-
sion.
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84% (95% CI 79–89%), respectively. Sensitivity and positive
predictive value increased with age; speciﬁcity and negative
predictive value decreased with age. Likelihood ratio positive
was 4.9 (95% CI 3.7–6.8) and was highest in the 30- to 49-
year age group, although the conﬁdence intervals were wide.
Likelihood ratio negative overall was 0.2 (95% CI 0.2–0.3). No
signiﬁcant age-related trend was observed in the likelihood
ratio–negative values. Interval likelihood ratios based on
quintiles of the screening systolic and diastolic BPs are
displayed in Table 5. Screening BP measurements performed
best in predicting true diagnostic category for participants
with diastolic BPs of <80 mm Hg and systolic BP of 118 to
129 mm Hg.
Discussion
This is, to our knowledge, the ﬁrst population based study in
sub-Saharan Africa that has assessed the validity of screening
BP measurements versus ABPM.
In addition to inﬂating the true prevalence of hypertension
in the community by 53% (from 17% to 27%), screening BP
measurements failed to identify a signiﬁcant proportion of the
population that was identiﬁed as having hypertension using
ABPM: Nearly half of the hypertensive participants in this
study had masked hypertension. Screening BP measurements
would have failed to identify this population. In addition, 4% of
the population had white coat hypertension and were at risk
of being placed on treatment unnecessarily.28,29 Overesti-
mating the total number of patients with hypertension while
failing to identify a signiﬁcant proportion of the population
with the condition would lead to inefﬁcient and ineffective use
of scarce health resources. Our ﬁndings imply that, similar to
the situation in developed-country settings, efforts to control
the burden and consequences of hypertension in sSA are
likely to be signiﬁcantly impaired by current screening
methods.
The prevailing consensus is that hypertension in develop-
ing countries is more prevalent in urban than rural areas30;
however, data from our study, conducted in rural Kenya,
indicate that hypertension is not exclusively an urban disease.
This is supported by the previously documented ﬁnding of a
high burden of stroke and heart failure in the area.17 In
addition, the recently published 2015 Kenyan Ministry of
Health STEPs survey, which used methods similar to the
screening strategy employed here, found a 25% prevalence of
raised BP in rural areas—remarkably similar to what we found
Table 4. Validity Measures of Casual BP Method Compared to ABPM
Age Category, y Sensitivity Speciﬁcity PPV NPV LR Positive LR Negative
18–29 0.0 (0.0–0.0) 95.0 (90.5–98.0) 0.0 (0.0–0.0) 83.3 (69.7–96.1) 0.0 (0.0–0.0) 1.1 (1.0–1.1)
30–39 9.7 (2.5–24.9) 98.4 (96.5–99.6) 55.6 (23.6–88.9) 84.1 (73.2–93.3) 6.1 (1.3–31.5) 0.9 (0.8–1.0)
40–49 60.8 (35.8–88.7) 91.8 (85.4–96.6) 63.6 (45.1–83.3) 90.9 (80.5–97.7) 7.5 (3.4–20.8) 0.4 (0.1–0.7)
50–59 87.5 (74.8–96.9) 74.8 (62.0–86.0) 72.3 (59.5–84.5) 88.6 (76.1–97.1) 3.4 (2.2–6.3) 0.2 (0.0–0.3)
60–69 91.2 (83.4–97.0) 71.6 (53.3–87.4) 86.0 (75.9–94.3) 80.6 (64.5–92.9) 3.2 (1.9–7.0) 0.1 (0.0–0.3)
70–79 94.2 (88.1–98.9) 24.4 (8.5–49.2) 81.7 (70.4–90.9) 54.5 (25.0–85.7) 1.2 (1.0–1.8) 0.2 (0.0–0.8)
≥80 92.1 (81.5–100.0) 31.2 (0.0–100.0) 84.2 (64.7–100.0) 50.0 (0.0–100.0) 1.3 (0.9–3.0) 0.2 (0.0–1.1)
All* 79.9 (73.0–86.0) 83.7 (79.1–87.9) 79.5 (74.0–84.6) 84.2 (78.6–89.3) 4.9 (3.7–6.8) 0.2 (0.2–0.3)
ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
*Summary measures are age standardized to the World Health Organization population.
Table 5. Interval LRs for Screening Systolic and Diastolic BPs
SBP Interval LRs DBP Interval LRs
SBP Interval (mm Hg) LR Positive LR Negative DBP Interval (mm Hg) LR Positive LR Negative
<118 0.0 (0.0–0.0) 1.0 (1.0–1.0) <73 7.3 (2.4–31.4) 0.6 (0.4–0.9)
118–129 7.2 (1.4–39.0) 0.8 (0.6–1.0) 74–80 9.8 (4.5–38.7) 0.3 (0.1–0.6)
130–142 3.1 (1.7–6.1) 0.4 (0.2–0.7) 80–85 4.6 (2.5–10.9) 0.4 (0.2–0.6)
143–159 1.0 (1.0–1.0) — 86–94 1.6 (1.1–2.3) 0.3 (0.0–0.7)
>160 1.0 (1.0–1.0) — >95 1.0 (1.0–1.0) —
SBP and DBP intervals were determined by dividing the screening blood pressure values into quintiles. Empty cells indicate that there was insufﬁcient data to calculate validity measures.
BP indicates blood pressure; DBP, diastolic blood pressure; LR, likelihood ratio; SBP, systolic blood pressure.
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on screening in our study.31 The prevalence of raised BP in
urban areas in the same (STEPs) survey was 21%. Conse-
quently, lifestyle habits related to urbanization may have a
smaller role in elevating BP in African populations than
previously thought.
Urinary sodium levels in Kiliﬁ were comparable to those
reported by Dahl in Alaskan eskimos in 1958, for which the
prevalence of hypertension was zero.32 In contrast, results
from Nairobi, Kenya, in the Intersalt study found lower
median 24-hour sodium levels of 53 mmol/day, with a 5%
prevalence of hypertension,33 although this was not age
standardized. Mean body mass index levels in our population
were well within the normal range. This combination of a
high prevalence of hypertension in a rural region with
relatively low levels of classic risk factors calls for more
detailed study into the pathogenesis of this important
condition in tropical Africa.
Previous studies in sSA using ABPM have found high
prevalence of the white coat effect among treated hyperten-
sive patients.34 Although we found white coat hypertension to
be present in 4% of the population, the more signiﬁcant
ﬁnding was the high prevalence of masked hypertension in 8%
of the population. Given the increased risk of cardiovascular
events in this population,21,35 strategies aimed at identifying
these individuals are urgently needed. The observation that
younger age is associated with masked hypertension36 may
help direct targeted ABPM at this group. It also may be
possible to identify individuals with masked hypertension by
measuring arterial stiffness indices.35
The strengths of this study include its population-based
design, the use of reference standard methods for deter-
mining BP, and utilization of a large and representative age-
stratiﬁed sample. Limitations include the potential bias
introduced by the nested case–control design used, despite
demonstration that this approach yields validity results
essentially similar to those of full cohort studies.18 As
expected from the sampling strategy used, participants who
underwent ABPM had higher screening systolic BP and were
slightly older than the baseline group. Weighting of analyses
to correct for the differential probability of undergoing ABPM
based on screening results may not have completely
eliminated the bias. In addition, a larger proportion of
screen-negative participants had poor-quality ABPM read-
ings; these limitations mean that although our reported
prevalence of masked hypertension was similar to that
reported in other studies,21,37,38 it may well have been
underestimated. The fact that BP measurements were done
at home and by nonmedical personnel could also have
reduced our ability to detect the white coat effect. Taken
together, probable underestimation of masked and white
coat hypertension suggest that there could have been more
participants who were misclassiﬁed using the screening
measurement method, possibly strengthening the case for
the use of ABPM.
Several issues must be considered before a recommenda-
tion to adopt ABPM for diagnosis of hypertension in sSA is
made. We observed a modest response rate, with 27% of
those referred for ABPM failing to undergo the procedure. This
suggests that there may be difﬁculties regarding acceptability
of ABPM in the population. Cost-effectiveness studies
assessing the potential beneﬁt of ABPM in sSA settings are
also needed, as are studies to determine whether BP deﬁned
by ABPM provides better targeting of BP-reduction strategies
to reduce vascular morbidity.
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